Empagliflozin treatment significantly reduces pulmonary artery (PA) blood pressure in patients with heart failure (HF), show findings from the randomized EMBRACE-HF trial.

Dr. Mikhail Kosiborod, with Saint Luke’s Mid America Heart Institute, and study co-authors say theirs is the first trial to demonstrate a “decongestion effect” of sodium-glucose cotransporter (SGLT)2 inhibition in people with HF via the direct measurement of PA hemodynamics.

Read the full MedwireNews article: Direct ‘decongestion’ effect shown for empagliflozin in HF